COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: On the first day of hospitalization of this study, which will be performed non-blindly, patients of the intervention group will receive 40 mg subcutaneous adalimumab made by Sinagen fa
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 70 Years
Inclusion criteria
Inclusion criteria: Severe COVID-19 (respiratory rate more than 30 per minute or oxygen saturation less than 90% or more than 50% lung parenchyma involvement on the patient's CT scan) Patient's consent Age: 60_70 years old
Exclusion criteria
Exclusion criteria: Fever (body temp above 40°C) Any active bacterial or fungal infection Positive blood and urine culture History of chronic obstructive pulmonary disease History of tuberculosis Heart failure Infectious skin wounds History of multiple sclerosis Very severe/critical stage of the disease (shock, encephalopathy, myocardial lesion, coagulation, and renal impairment) abnormal liver tests in the form of liver enzymes more than 2 times normal GFR less than or equal to 30
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-reactive protein (CRP). Timepoint: First and 5th day. Method of measurement: using latex agglutination tests and a bionic CRP quantitative detection kit.;Lactate Dehydrogenase (LDH). Timepoint: First and 5th day. Method of measurement: routine commercial kits (Pars Azmoon Co.,Iran).;SpO2 level. Timepoint: First and 5th day. Method of measurement: by pulse oximeter.;Respiratory rate per minute. Timepoint: First and 5th day. Method of measurement: Counting the number of breaths for one minute by counting how many times the chest rises.;Hospitalization stay. Timepoint: discharge time. Method of measurement: Counting the number of days hospitalized. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehrdad farrokhnia
Kerman University of Medical Sciences
Outcome results
None listed